Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$19.33
0.150.78%
At close: -
$19.33
0.000.00%
After Hours: Mar 21, 4:01 PM EDT
Comments
Loading...
NovoCure Analyst Ratings and Price Targets | NASDAQ:NVCR | Benzinga
NovoCure Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for NovoCure Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Piper Sandler
Evercore ISI Group
Wells Fargo
JP Morgan
1calculated from analyst ratings
Analyst Ratings for NovoCure
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 01/14/2025 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 12/13/2024 | Buy Now | — | Piper Sandler | Jason Bednar54% | $28 → $42 | Maintains | Overweight | Get Alert |
| 12/03/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | $30 → $38 | Maintains | Buy | Get Alert |
| 12/02/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | $30 → $38 | Reiterates | Buy → Buy | Get Alert |
| 12/02/2024 | Buy Now | — | Evercore ISI Group | Vijay Kumar54% | $18 → $30 | Upgrade | In-Line → Outperform | Get Alert |
| 11/21/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 10/16/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | $24 → $30 | Upgrade | Neutral → Buy | Get Alert |
| 10/01/2024 | Buy Now | — | Evercore ISI Group | Vijay Kumar54% | $21 → $18 | Maintains | In-Line | Get Alert |
| 07/26/2024 | Buy Now | — | Wells Fargo | Larry Biegelsen69% | $42 → $40 | Maintains | Overweight | Get Alert |
| 07/26/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | $22 → $24 | Maintains | Neutral | Get Alert |
| 07/02/2024 | Buy Now | — | Evercore ISI Group | Vijay Kumar54% | $14.5 → $20 | Maintains | In-Line | Get Alert |
| 06/04/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | $22 → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 05/02/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | $24 → $22 | Maintains | Neutral | Get Alert |
| 04/10/2024 | Buy Now | — | Piper Sandler | Jason Bednar54% | $25 → $28 | Reiterates | Overweight → Overweight | Get Alert |
| 04/03/2024 | Buy Now | — | Wells Fargo | Larry Biegelsen69% | $49 → $42 | Maintains | Overweight | Get Alert |
| 03/27/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | $22 → $24 | Maintains | Neutral | Get Alert |
| 03/19/2024 | Buy Now | — | JP Morgan | Jessica Fye68% | $15 → $17 | Maintains | Neutral | Get Alert |
| 03/12/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | $22 → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 02/23/2024 | Buy Now | — | Evercore ISI Group | Vijay Kumar54% | $14 → $15 | Maintains | In-Line | Get Alert |
| 02/22/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | $21 → $22 | Maintains | Buy | Get Alert |
| 08/29/2023 | Buy Now | — | Wells Fargo | Larry Biegelsen69% | $102 → $49 | Maintains | Overweight | Get Alert |
| 08/28/2023 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | → $25 | Downgrade | Buy → Neutral | Get Alert |
| 08/08/2023 | Buy Now | — | Piper Sandler | Jason Bednar54% | → $45 | Upgrade | Neutral → Overweight | Get Alert |
| 08/04/2023 | Buy Now | — | SVB Leerink | Jonathan Chang38% | → $51 | Initiates | → Outperform | Get Alert |
| 07/31/2023 | Buy Now | — | Evercore ISI Group | Vijay Kumar54% | → $33 | Upgrade | Underperform → In-Line | Get Alert |
| 07/28/2023 | Buy Now | — | Wells Fargo | Larry Biegelsen69% | $104 → $102 | Maintains | Overweight | Get Alert |
| 07/27/2023 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | → $85 | Reiterates | Buy → Buy | Get Alert |
| 06/07/2023 | Buy Now | — | Piper Sandler | Jason Bednar54% | $67 → $62 | Maintains | Neutral | Get Alert |
| 06/07/2023 | Buy Now | — | Wedbush | David Nierengarten62% | $53 → $46 | Upgrade | Underperform → Neutral | Get Alert |
| 06/06/2023 | Buy Now | — | Truist Securities | Gregory Fraser65% | → $95 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2023 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | → $115 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | — | Wells Fargo | Larry Biegelsen69% | $70 → $104 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 05/05/2023 | Buy Now | — | Truist Securities | Gregory Lewis70% | $102 → $95 | Maintains | Buy | Get Alert |
| 05/04/2023 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | $130 → $115 | Maintains | Buy | Get Alert |
| 03/17/2023 | Buy Now | — | JP Morgan | Jessica Fye68% | $99 → $50 | Downgrade | Neutral → Underweight | Get Alert |
| 01/17/2023 | Buy Now | — | Piper Sandler | Jason Bednar54% | $70 → $80 | Maintains | Neutral | Get Alert |
| 01/06/2023 | Buy Now | — | JP Morgan | Jessica Fye68% | $86 → $99 | Maintains | Neutral | Get Alert |
| 01/06/2023 | Buy Now | — | Wells Fargo | Larry Biegelsen69% | $89 → $107 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/29/2022 | Buy Now | — | Wells Fargo | Larry Biegelsen69% | $74 → $89 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 10/28/2022 | Buy Now | — | Truist Securities | Gregory Fraser65% | $105 → $102 | Maintains | Buy | Get Alert |
| 10/28/2022 | Buy Now | — | Wells Fargo | Larry Biegelsen69% | $70 → $74 | Maintains | Equal-Weight | Get Alert |
| 10/28/2022 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | $115 → $100 | Maintains | Buy | Get Alert |
| 10/24/2022 | Buy Now | — | Piper Sandler | Jason Bednar54% | $90 → $70 | Downgrade | Overweight → Neutral | Get Alert |
| 07/29/2022 | Buy Now | — | Truist Securities | Gregory Fraser65% | $118 → $105 | Maintains | Buy | Get Alert |
| 07/05/2022 | Buy Now | — | Evercore ISI Group | Vijay Kumar54% | — | Downgrade | In-Line → Underperform | Get Alert |
| 05/16/2022 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar38% | → $115 | Initiates | → Buy | Get Alert |
| 05/13/2022 | Buy Now | — | Piper Sandler | Jason Bednar54% | $125 → $100 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for NovoCure (NVCR) stock?
The latest price target for NovoCure (NASDAQ:NVCR) was reported by HC Wainwright & Co. on January 14, 2025. The analyst firm set a price target for $38.00 expecting NVCR to rise to within 12 months (a possible 96.59% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NovoCure (NVCR)?
The latest analyst rating for NovoCure (NASDAQ:NVCR) was provided by HC Wainwright & Co., and NovoCure reiterated their buy rating.
When was the last upgrade for NovoCure (NVCR)?
The last upgrade for NovoCure Ltd happened on December 2, 2024 when Evercore ISI Group raised their price target to $30. Evercore ISI Group previously had an in-line for NovoCure Ltd.
When was the last downgrade for NovoCure (NVCR)?
The last downgrade for NovoCure Ltd happened on August 28, 2023 when HC Wainwright & Co. changed their price target from N/A to $25 for NovoCure Ltd.
When is the next analyst rating going to be posted or updated for NovoCure (NVCR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NovoCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NovoCure was filed on January 14, 2025 so you should expect the next rating to be made available sometime around January 14, 2026.
Is the Analyst Rating NovoCure (NVCR) correct?
While ratings are subjective and will change, the latest NovoCure (NVCR) rating was a reiterated with a price target of $38.00 to $38.00. The current price NovoCure (NVCR) is trading at is $19.33, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.